日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

伊斯卡利单抗(CFZ533)治疗增生性狼疮性肾炎患者的疗效、药代动力学和安全性:一项随机、双盲、安慰剂对照的II期研究

Shen, Nan; Weinmann-Menke, Julia; Malvar, Ana; Serra-Roma, André; Weiss, Markus; Danekula, Rambabu; Sips, Carole; Rohr, Jan; Felten, Renaud; Gergely, Peter; Shisha, Tamas

Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort

严重难治性系统性红斑狼疮试点定义的患病率和结果:来自亚太多国队列的观察

Kandane-Rathnayake, Rangi; Louthrenoo, Worawit; Lau, C S; Hamijoyo, Laniyati; Cho, Jiacai; Lateef, Aisha; Luo, Shue Fen; Wu, Yeong-Jian; Navarra, Sandra; Zamora, Leonid; Li, Zhanguo; Chen, Yi-Hsing; Oon, Shereen; Chan, Madelynn; Sockalingam, Sargunan; Hao, Yanjie; Zhang, Zhuoli; Bae, Sang-Cheol; Kikuchi, Jun; Takeuchi, Tsutomu; Katsumata, Yasuhiro; Basnayake, Bmdb; Goldblatt, Fiona; O'Neill, Sean; Pek Ling Ng, Kristine; Tugnet, Nicola; Sapsford, Mark; Poh, Yih Jia; Tee, Cherica; Tee, Michael; Ohkubo, Naoaki; Lefeber, Adrienne O'Donnell; Shisha, Tamas; Tanaka, Yoshiya; Golder, Vera; Nikpour, Mandana; Hoi, Alberta; Gergely, Peter; Morand, Eric

Design of an implementation research study for a digital omnichannel community engagement and risk communication intervention for the prevention and control of vector-borne diseases in India: the OMNIVEC-India study protocol

针对印度媒介传播疾病预防和控制的数字化全渠道社区参与和风险沟通干预措施,设计一项实施研究方案:OMNIVEC-India 研究方案

Rodrigues, Rashmi; Dhatrak, Amey; Bal, Madhusmita; Nongrum, Melari Shisha; Kumar, Neeraj; Sarkar, Rajiv; Agrawal, Twinkle; Mundra, Anuj; Praharaj, Ira; Singh, Jyoti; Zode, Mrunali; Roy, Sudipto; Kandpal, Vani; Lyngdoh, Tanica

Barriers in implementing cancer prevention programme in North Eastern India: A case study from Meghalaya

印度东北部癌症预防项目实施中的障碍:以梅加拉亚邦为例

Pohsnem, Fellicita; Nongrum, Melari Shisha; Sarkar, Rajiv; Albert, Sandra

Factors influencing delayed cancer health seeking in Meghalaya, Northeast India: A qualitative study

影响印度东北部梅加拉亚邦癌症患者延迟就医的因素:一项定性研究

Dkhar, Barilin; Khongwir, Carmenia; Mawrie, Uniqueky Gratis; Pohsnem, Fellicita; Dhar, Redolen Rose; Mawlong, Anisha; Sarkar, Rajiv; Nongrum, Melari Shisha; Albert, Sandra

Endoscopic Assessment of Cholesteatoma Following Microscope Assisted Tympano: Mastoidectomy: Study design: a cross section descriptive study

显微镜辅助鼓室乳突切除术后胆脂瘤的内镜评估:研究设计:横断面描述性研究

Phanbuh, Daphylla Shisha; Meher, Ravi; Singh, Ishwar; Taneja, Harish Chandra; Wadhwa, Vikram; Kumar, Jyoti

Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy

用于狼疮治疗的 Toll 样受体 7/8 拮抗剂 MHV370 的临床前特性研究

Stuart Hawtin ,Cédric André ,Géraldine Collignon-Zipfel ,Simone Appenzeller ,Bettina Bannert ,Lea Baumgartner ,Damian Beck ,Claudia Betschart ,Thomas Boulay ,Hermine I Brunner ,Melanie Ceci ,Jonathan Deane ,Roland Feifel ,Enrico Ferrero ,Diego Kyburz ,Frederique Lafossas ,Pius Loetscher ,Christina Merz-Stoeckle ,Pierre Michellys ,Barbara Nuesslein-Hildesheim ,Friedrich Raulf ,James S Rush ,Giulia Ruzzante ,Thomas Stein ,Samantha Zaharevitz ,Grazyna Wieczorek ,Richard Siegel ,Peter Gergely ,Tamas Shisha ,Tobias Junt

First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults

MHV370(一种 Toll 样受体 7 和 8 的双重抑制剂)在健康成年人中的安全性、药代动力学和药效学的首次人体研究

Shisha, Tamas; Posch, Maximilian G; Lehmann, Jeanette; Feifel, Roland; Junt, Tobias; Hawtin, Stuart; Schuemann, Jens; Avrameas, Alexandre; Danekula, Rambabu; Misiolek, Patrycja; Siegel, Richard; Gergely, Peter

COVID associated mucormycosis: A preliminary study from a dedicated COVID Hospital in Delhi

新冠病毒相关毛霉菌病:德里一家新冠肺炎定点医院的初步研究

Meher, Ravi; Wadhwa, Vikram; Kumar, Vikas; Shisha Phanbuh, Daphylla; Sharma, Raman; Singh, Ishwar; Rathore, P K; Goel, Ruchi; Arora, Ritu; Garg, Sandeep; Kumar, Suresh; Kumar, Jyoti; Agarwal, Munisha; Singh, Meeta; Khurana, Nita; Sagar, Tanu; Manchanda, Vikas; Saxena, Sonal

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

一项随机、双盲试验,旨在证明GP2013与参考利妥昔单抗联合甲氨蝶呤治疗活动性类风湿关节炎患者的生物等效性

Smolen, Josef S; Cohen, Stanley B; Tony, Hans-Peter; Scheinberg, Morton; Kivitz, Alan; Balanescu, Andra; Gomez-Reino, Juan; Cen, Liyi; Zhu, Peijuan; Shisha, Tamas